Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8BYU3
|
|||
| Drug Name |
BAY2599023
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Haemophilia A [ICD-11: 3B10.0; ICD-9: 286] | Phase 1/2 | [1] | |
| Company |
Bayer Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor VIII (F8) | Target Info | . | [1] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Platelet degranulation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | ||||
| COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Cargo concentration in the ER | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03588299) A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.